Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Payer

- PMLiVE

Kite Pharma soars after positive CAR-T data in lymphoma

Looks to become first marketed CAR-T drug as phase II results pave way for US filing

Novartis building

Anxiety over CAR-T follows Novartis closure of cell therapy unit

Firm maintains lead ALL project still on course for 2017 filings despite restructuring

- PMLiVE

Ireland ekes out major savings in drug pricing deal

Four-year pharma agreement will save an estimated €600m

- PMLiVE

Defining value: has anyone asked the patient?

The real-world challenges they face give patients unique views on 'value'

- PMLiVE

European pharma considering medicine pricing shakeup

EFPIA will later this month discuss proposals for a value-based pricing system

- PMLiVE

Baxalta makes $1.7bn play for slice of CAR-T market

Three-year alliance with Precision BioSciences to expand immuno-oncology portfolio

- PMLiVE

The Maverick: giving medicines away free

Co-op biotech founder Andrew Hessel on how he wants to change the way medicines are discovered and paid for

- PMLiVE

Money-back guarantee

Why doesn’t this apply to the drugs and devices that we use?

CAR-T cancer therapy passes milestone

Belgianbiotech Celyad's cancer immunotherapy will now be tested at higher doses

- PMLiVE

Roche faces Kadcyla pricing pressure in the UK

Leading breast cancer charity calls on firmto reduce the drug's cost

- PMLiVE

Taking a strategic approach

Janssen's Cyril Titeux on responding to the industry's pricing, access and reputational challenges

- PMLiVE

PCSK9 inhibitors vastly over-priced, says ICER report

Cost of new Amgen and Sanofi drugs comes under fire

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links